Please login to the form below

Not currently logged in
Email:
Password:

iBio and GE Healthcare extend Alliance into plant-based vaccines

Will use technology to make plants produce proteins

iBio and GE Healthcare have entered an alliance to commercialise plant-based technologies for the manufacture of biopharmaceuticals and vaccines, extending a collaboration originally formed in 2010.

The latest agreement involves the creation of a single facility with the ability to reduce the capital and operating costs of biotherapeutic and vaccine manufacture.

It combines GE Healthcare's technologies to manufacture biopharmaceuticals and other protein-based therapeutics, with iBio's own platform iBioLaunch.

This tool causes plants to rapidly produce high quantities of proteins that can then be used in vaccines.

It is based on gene expression technology, which can be scaled-up within low cost, controlled-growth facilities, according to iBio.

This provides potential to manufacture proteins that cannot be commercially produced in any other system.

The agreement will also see iBio's R&D collaborator, Fraunhofer US Center for Molecular Biotechnology (CMB) continue its involvement in the iBioLaunch platform.

Previous work involving the plant-technology includes an alliance between iBio and the Bill & Melinda Gates Foundation that has been used to produce an avian influenza vaccine candidate that successfully completed phase I clinical trials recently.

27th July 2012

Share



Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Litmus MME

LITMUS places the development of strong physician relationships at the centre of every program and has established a new standard...

Latest intelligence

Designing Human Experiences
Applying science to the creative process to improve lives...
Assured Global Delivery at The Right Temperature®
CSafe Global partners with DHL Global Forwarding to assure pharmaceutical manufacturer successful temperature sensitive delivery to South America....
The changing regulatory environment
Code of practice changes are encouraging transparency in pharma/HCP relationships...